$1.88
0[0.00%]
At close: Apr 23
$1.88
0[0.00%]
PreMarket: 4:02PM EDT
Vor Biopharma
(NASDAQ:VOR)Vor Biopharma Stock (NASDAQ:VOR), Analyst Ratings, Price Targets, Predictions
Vor Biopharma Inc has a consensus price target of $14.25, established from looking at the 36 latest analyst ratings. The last 3 analyst ratings were released from Wedbush, JMP Securities, and Stifel on April 23, 2024, March 22, 2024, and March 21, 2024. With an average price target of $11.67 between Wedbush, JMP Securities, and Stifel, there's an implied 520.57% upside for Vor Biopharma Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
Wedbush
JMP Securities
Stifel
Oppenheimer
HC Wainwright & Co.
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Vor Biopharma
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 04/23/2024 | VOR | Buy Now | Vor Biopharma | $1.88 | 485.11% | Wedbush | David Nierengarten | → $11 | Reiterates | Outperform → Outperform | Get Alert |
| 03/22/2024 | VOR | Buy Now | Vor Biopharma | $1.88 | 538.3% | JMP Securities | Silvan Tuerkcan | → $12 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 03/21/2024 | VOR | Buy Now | Vor Biopharma | $1.88 | 538.3% | Stifel | Stephen Willey | $15 → $12 | Maintains | Buy | Get Alert |
| 03/21/2024 | VOR | Buy Now | Vor Biopharma | $1.88 | 485.11% | Wedbush | David Nierengarten | → $11 | Reiterates | Outperform → Outperform | Get Alert |
| 03/21/2024 | VOR | Buy Now | Vor Biopharma | $1.88 | 697.87% | Oppenheimer | Matthew Biegler | $17 → $15 | Reiterates | Outperform → Outperform | Get Alert |
| 03/21/2024 | VOR | Buy Now | Vor Biopharma | $1.88 | 830.85% | HC Wainwright & Co. | Swayampakula Ramakanth | → $17.5 | Reiterates | Buy → Buy | Get Alert |
| 01/18/2024 | VOR | Buy Now | Vor Biopharma | $1.88 | 485.11% | Wedbush | David Nierengarten | → $11 | Reiterates | Outperform → Outperform | Get Alert |
| 08/14/2023 | VOR | Buy Now | Vor Biopharma | $1.88 | 538.3% | JMP Securities | Silvan Tuerkcan | → $12 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 08/11/2023 | VOR | Buy Now | Vor Biopharma | $1.88 | 485.11% | Wedbush | David Nierengarten | $18 → $11 | Maintains | Outperform | Get Alert |
| 08/11/2023 | VOR | Buy Now | Vor Biopharma | $1.88 | 830.85% | HC Wainwright & Co. | Swayampakula Ramakanth | → $17.5 | Reiterates | Buy → Buy | Get Alert |
| 06/12/2023 | VOR | Buy Now | Vor Biopharma | $1.88 | 830.85% | HC Wainwright & Co. | Swayampakula Ramakanth | → $17.5 | Reiterates | Buy → Buy | Get Alert |
| 05/16/2023 | VOR | Buy Now | Vor Biopharma | $1.88 | 830.85% | HC Wainwright & Co. | Swayampakula Ramakanth | → $17.5 | Reiterates | Buy → Buy | Get Alert |
| 05/16/2023 | VOR | Buy Now | Vor Biopharma | $1.88 | 857.45% | JonesTrading | Justin Walsh | → $18 | Initiates | → Buy | Get Alert |
| 05/15/2023 | VOR | Buy Now | Vor Biopharma | $1.88 | 857.45% | Oppenheimer | Matthew Biegler | → $18 | Reiterates | Outperform → Outperform | Get Alert |
| 05/12/2023 | VOR | Buy Now | Vor Biopharma | $1.88 | 857.45% | Wedbush | David Nierengarten | → $18 | Reiterates | Outperform → Outperform | Get Alert |
| 03/24/2023 | VOR | Buy Now | Vor Biopharma | $1.88 | 751.06% | Truist Securities | Stephen Willey | $17 → $16 | Maintains | Buy | Get Alert |
| 03/24/2023 | VOR | Buy Now | Vor Biopharma | $1.88 | 751.06% | Stifel | Stephen Willey | $17 → $16 | Maintains | Buy | Get Alert |
| 03/24/2023 | VOR | Buy Now | Vor Biopharma | $1.88 | 857.45% | Oppenheimer | Matthew Biegler | → $18 | Reiterates | → Outperform | Get Alert |
| 03/24/2023 | VOR | Buy Now | Vor Biopharma | $1.88 | 538.3% | JMP Securities | Silvan Tuerkcan | → $12 | Reiterates | → Market Outperform | Get Alert |
FAQ
What is the target price for Vor Biopharma (VOR)?
The latest price target for Vor Biopharma (NASDAQ: VOR) was reported by Wedbush on April 23, 2024. The analyst firm set a price target for $11.00 expecting VOR to rise to within 12 months (a possible 485.11% upside). 15 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Vor Biopharma (VOR)?
The latest analyst rating for Vor Biopharma (NASDAQ: VOR) was provided by Wedbush, and Vor Biopharma reiterated their outperform rating.
When was the last upgrade for Vor Biopharma (VOR)?
There is no last upgrade for Vor Biopharma.
When was the last downgrade for Vor Biopharma (VOR)?
There is no last downgrade for Vor Biopharma.
When is the next analyst rating going to be posted or updated for Vor Biopharma (VOR)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Vor Biopharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Vor Biopharma was filed on April 23, 2024 so you should expect the next rating to be made available sometime around April 23, 2025.
Is the Analyst Rating Vor Biopharma (VOR) correct?
While ratings are subjective and will change, the latest Vor Biopharma (VOR) rating was a reiterated with a price target of $0.00 to $11.00. The current price Vor Biopharma (VOR) is trading at is $1.88, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.